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In Brief
In a wide variety of sporadic
malignancies, promoter methylation of
the RASSF1 gene is associated with
tumor invasion and metastasis. Vlahov
et al. show that the clinical phenotype is
driven by both RASSF1A loss and the
independently transcribed RASSF1C
isoform, which promotes SRC activation,
pseudo-EMT, and b-catenin/YAP1-
dependent invasion of tumor cells.
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Tumor progression to invasive carcinoma is associ-
ated with activation of SRC family kinase (SRC,
YES, FYN) activity and loss of cellular cohesion. The
hippo pathway-regulated cofactor YAP1 supports
the tumorigenicity of RAS mutations but requires
both inactivation of hippo signaling and YES-medi-
ated phosphorylation of YAP1 for oncogenic activity.
Exactly how SRC kinases are activated and hippo
signaling is lost in sporadic human malignancies re-
mains unknown. Here, we provide evidence that hip-
po-mediated inhibition of YAP1 is lost upon promoter
methylationof theRASeffectorandhippokinasescaf-
fold RASSF1A. We find that RASSF1A promoter
methylation reduces YAPphospho-S127, which dere-
presses YAP1, and actively supports YAP1 activation
by switching RASSF1 transcription to the indepen-
dently transcribed RASSF1C isoform that promotes
Tyr kinase activity. Using affinity proteomics, prox-
imity ligation, and real-time molecular visualization,
we find that RASSF1C targets SRC/YES to epithelial
cell-cell junctions and promotes tyrosine phosphory-
lation of E-cadherin, b-catenin, and YAP1. RASSF1A
restricts SRC activity, preventing motility, invasion,
and tumorigenesis in vitro and in vivo, with epigenetic
inactivation correlating with increased inhibitory
pY527-SRC in breast tumors. These data imply that
distinct RASSF1 isoforms have opposing functions,
which provide a biomarker for YAP1 activation and
explain correlations of RASSF1 methylation with
advanced invasive disease in humans. The ablation
of epithelial integrity together with subsequent YAP1
nuclear localization allows transcriptional activation
of b-catenin/TBX-YAP/TEAD target genes, including
Myc, and an invasive phenotype. These findings
define gene transcript switching as a tumor suppres-
sor mechanism under epigenetic control.Current BINTRODUCTION
Recent advances have highlighted that YES-associated protein
(YAP1) supports KRAS tumorigenicity and assists in the mainte-
nance of transformed phenotypes [1]. YAP1 drives proliferation
by acting as a cofactor for TEAD transcriptional regulators, an
activity which is restricted by hippo pathway-mediated disrup-
tion of TEAD association. In model systems, genetic ablation of
core hippo pathway components leads to increased tumorigen-
esis [1]. In human tumors, failure to activate LATS1 due to either
GNAQ mutations in uveal melanoma or through inactivation of
NF2/merlin in the tumor-prone neurofibromatosis syndrome pre-
vent this inhibitory signal and make YAP1 permissive for activa-
tion [1]. Similarly, stromal mechanics and genetic instability are
reported to trigger the hippo pathway and present a tumor bar-
rier, but as with GNAQ mutations and germline defects in NF2/
merlin, these mechanisms appear to be independent of the hip-
po kinase/MST itself [1]. Identification of the core hippo pathway
by proteomics has revealed the main direct activators of MST ki-
nases to be SAV1 and RASSFs [2], which although infrequently
mutated in cancers [3] have germline and epigenetic alterations,
particularly in RASSF1A, that accelerate tumor onset and in-
crease tumorigenicity [4, 5]. Moreover, RASSF1A activation of
the hippo pathway both restricts YAP1 binding to TEAD [6] and
is a direct substrate of RAS signaling in the pancreas [7], sup-
porting the potential crosstalk in pancreatic tumor development
[8, 9]. Intriguingly, methylation of the CpG island (CGI) spanning
the promoter and first exon of RASSF1 has widespread prog-
nostic value for disease-free and poor overall survival in all major
sporadic cancers [10]. Thus, loss of RASSF1A expression in
RASSF1-methylated tumors is likely to contribute to reduced
hippo pathway-mediated repression of YAP1, due to direct
activation of MST kinases and the subsequent interaction and
activation of LATS1 [4, 11–14]. This RASSF1A/MST2-promoted
LATS1 activity is targeted toward YAP1 [12], resulting in in-
creased pS127-YAP [15] and decreased YAP-TEAD oncogenic
behavior [6, 15].
Hahn and colleagues recently highlighted that, by using a
YAP1 mutant for all LATS1 phosphorylation sites (5SA) including
the inhibitory S127-YAP1 phosphorylation, while permissive,
required additional phosphorylation of Y357-YAP1 by the SRCiology 25, 3019–3034, December 7, 2015 ª2015 The Authors 3019
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Figure 1. Loss of RASSF1A Mediates Nuclear Localization of YAP1
(A) Correlation of RASSF1 methylation levels (meRASSF1) below 0.3, between 0.3 and 0.5, and above 0.5 with loss of inhibitory YAP1-phospho-Ser127 (pS127-
YAP1) in the cancer genome atlas (TCGA) data sets (cBioportal).
(legend continued on next page)
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family kinase (SFK) YES to activate transcription [16]. Moreover,
they found that the main tumorigenic consequence of APC loss
in colorectal cancer was due to a subset of b-catenin genes that
were YAP1 dependent. Thus, YAP1 may serve to integrate WNT
and RAS signaling in order to trigger epithelial-to-mesenchymal
transition (EMT) and invasive disease [17]. Tumor progression to
invasive carcinoma is associated with constitutive loss of cellular
cohesion, leading to EMT, increased cellular motility, and inva-
sion into the surrounding tissues [18]. Activation of SFKs is asso-
ciated with increased tumor invasion and metastasis through
initial destabilization of epithelial cell-cell junctions. Mechanisti-
cally, this occurs through direct phosphorylation of E-cadherin,
p120-catenin, and b-catenin [19–21]. Phosphorylation of E-
cadherin promotes internalization, whereas phosphorylation of
b-catenin decreases its affinity for E-cadherin, allowing nuclear
localization where it serves as a transcriptional co-activator of
TCF/Lef1 factors [22, 23]. The identification of a YAP1-b-catenin
transcriptional program specified a novel role for b-catenin in
activating transcription via T-box factors rather than TCF, par-
ticularly in cancers [16]. Importantly, YAP1 has also been shown
to cooperate with b-catenin at TEAD-dependent promoters to
induce cell proliferation in the heart and during tumorigenesis
[24].
Here, we identify thatRASSF1CGImethylation correlates with
hippo pathway inactivation and loss of pS127-YAP1 in sporadic
malignancies and provide evidence for the association of this
methylation with invasive behavior in cancers, such as breast,
bladder, and in gliomas. CGI methylation restricts primary
transcript expression but can additionally promote switching
to alternative gene promoters or influence splicing, implying
that epigenetic regulation may modulate the relative levels of
gene isoforms rather than simply silence gene expression [25].
In tumors with RASSF1 CGI methylation, an alternative isoform,
RASSF1C, is expressed from an internal promoter and has been
suggested to promote motility and invasive disease [26, 27]. We
find that RASSF1C actually supports tumorigenesis by promot-
ing SRC/YES-mediated phosphorylation of E-cadherin, b-cate-
nin, and YAP1, disrupting cell-cell contacts and initiating an
EMT-like response. RASSF1A also binds to SFKs but addition-
ally scaffolds CSK, potentially through an exon 1a-encoded C1
domain, not present in RASSF1C, which inhibits SFKs andmain-
tains epithelial integrity. In the absence of RASSF1A, RASSF1C
promotes tyrosine phosphorylation of b-catenin and YAP1, re-
sulting in their re-localization to the nucleus and transcriptional
activation of the TBX target genes, BCL2L1, BIRC5 [16], and
cMyc [28]. Analyses of invasive breast tumor data sets in-
dicate an inverse correlation of high RASSF1A methylation/low(B) Immunofluorescence detection of YAP1 and pS127-YAP1 in U2OS cells trans
depicted in Figure S1, histogram indicating the comparative nuclear and cytopla
immunofluorescence distribution is shown. (Bottom right) The corresponding im
shown. (Far right) Distribution of DAPI (blue), YAP1 (red), and pS127-YAP1 (gree
(average of n = 29).
(C) Schematic representation of the RASSF1A and RASSF1C isoforms (top), the
(bottom).
(D) Immunofluorescence detection of YAP1 and pS127-YAP1 in U2OS cells tran
RASSF1C as indicated. Images are representative of two independent siRASSF1
were designed (see Figures S1G and S1H). Distribution of DAPI (blue), YAP1
immunofluorescence is shown (bottom).
All scale bars represent 20 mm.
Current BpS127-YAP1 with SRC activation and the expression of inva-
sion-associated transcripts. To validate a role in motility and in-
vasion, we demonstrate that RASSF1C directly promotes SFK-
dependent motility, 3D invasion of mammospheres and tumor
spread in vivo. These data imply that SFK activation/inactivation
relies on distinct RASSF1 isoforms, presenting a mechanism
for YAP1 activation in sporadic tumors and explains the clinical
correlation of RASSF1 methylation with advanced invasive
disease.
RESULTS
Switching of RASSF1 Isoforms Induces Nuclear
Localization of YAP1
RASSF1A is a hippo pathway scaffold that switches YAP1 as-
sociation from oncogenic TEAD transcriptional complexes to
tumor-suppressive YAP1/p73 [6]. As RASSF1A expression is
lost in multiple cancers and associates with poor outcome,
we wanted to determine whether this was a route through
which the hippo pathway may be inactivated in sporadic can-
cers. To address this, we explored YAP1 protein information in
data sets of tumors where RASSF1 is known to be methylated,
clinically significant [10], and for which pS127-YAP information
was available. We found that methylation of RASSF1-1a (re-
presenting gene silencing) significantly correlates with low
pS127-YAP1 in glioma, bladder, and breast cancer cohorts
(Figure 1A), suggesting that YAP1 may be nuclear and active
in RASSF1-methylated tumors. To test this correlation, we tar-
geted RASSF1A expression in U2OS cells, unmethylated for
RASSF1A, with siRNAs and observed lower pS127-YAP1 in
line with the clinical data (Figures S1A and S1C). Intriguingly,
in contrast to siRNA targeting exons common to all isoforms
(siRASSF1), specific ablation of the RASSF1A isoform resulted
in elevated nuclear localization of YAP1, indicating that
reduced pS127-YAP1 appears required but insufficient for nu-
clear localization of YAP1 (Figure 1B). In keeping with a loss
of hippo pathway activity, the loss of RASSF1 or RASSF1A
led to a decrease in the phosphorylation of the core hippo ki-
nases MST1/2 and LATS1 (Figure S1C) and was conversely
increased by overexpression of RASSF1A in both U2OS and
H1299 (methylated) cells (Figure S1D). RASSF1C transcripts
are often present in RASSF1A-methylated tumors due to
expression from a distinct promoter and are susceptible to
siRASSF1, but not siRASSF1A (Figures 1C, S1B, and S1C)
[27]. To determine whether the RASSF1C transcript was
responsible for elevated nuclear YAP1 upon siRASSF1A, we
designed derivatives of RASSF1A or RASSF1C to be resistantfected with siNT, siRASSF1A, and siRASSF1 (top). (Bottom left) Using vectors
smic levels of YAP1 (bottom) and pS127 (top) determined by intensity of the
munoblot showing the nuclear, cytoplasmic, and total lysate levels of YAP1 is
n) across equatorial cell vector determined by immunofluorescence is shown
location of the sequence for the siRNAs used (middle), and protein functions
sfected with siNT, siRASSF1, and siRNA-resistant versions of RASSF1A and
oligos to which two siRNA restraint isoforms of both RASSF1A and RASSF1C
(red), and pS127-YAP1 (green) across equatorial cell vector determined by
iology 25, 3019–3034, December 7, 2015 ª2015 The Authors 3021
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Figure 2. RASSF1C Binds to and Activates SFKs
(A) Proteomic identification of RASSF1A and RASSF1C immunoprecipitates by tandem MS/MS.
(B) HA-tag immunoprecipitation from 293T cells transfected with MYC-SRC (left), MYC-FYN (middle), or MYC-YES (right) in combination with HA-RASSF1A or
HA-RASSF1C, analyzed by immunoblotting.
(C) CSK immunoprecipitation from H1299 cells transfected with FLAG-RASSF1A or FLAG-RASSF1C. The precipitates along with input fractions were analyzed
by immunoblotting.
(D) RASSF1 immunoprecipitation from HeLa cells, immunoblotted for CSK, SRC, and RASSF1A.
(legend continued on next page)
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to the two distinct RASSF1 siRNAs, allowing a direct com-
parison. RASSF1C expression restored nuclear YAP1 in
siRASSF1-transfected cells without affecting the pS127-
YAP1 levels, whereas RASSF1A failed to do so (Figures 1D,
S1E, S1G, and S1H). Thus, reduced hippo signaling and
pS127-YAP levels appear effectively uncoupled from auto-
matic nuclear localization, in keeping with the recently demon-
strated requirement for tyrosine phosphorylation to mediate
the transition [29]. Intriguingly, phosphotyrosine immunopre-
cipitates of U2OS cells demonstrate that RASSF1C promotes
increased tyrosine phosphorylation of YAP1 (Figure S1F).
This indicates that promoter methylation of RASSF1-1a, which
inhibits RASSF1 isoform A expression, reduces hippo signaling
and inhibitory pYAP-S127 but favors the nuclear localization of
YAP1 via RASSF1-1a-independent transcription of RASSF1
isoform C.
RASSF1 Isoforms Interact with and Differentially
Regulate SFKs
To determine the mechanism of how RASSF1C promotes tyro-
sine phosphorylation and nuclear localization of YAP, we per-
formed a proteomic screen of both isoforms to identify novel
protein-protein interactions (Figure 2A). We screened RASSF1
immunoprecipitates for candidates and found that both RASSF1
isoforms bind the tyrosine kinases c-SRC, FYN, and YES (Fig-
ure 2B); interestingly, however, RASSF1A had an additional
unique association with the SRC inhibitory kinase, CSK (Figures
2C and S2G). The binding of endogenous RASSF1A to CSK was
confirmed in HeLa cells, unmethylated for RASSF1A (Figure 2D),
and could also be demonstrated to be direct using bacterially
purified proteins for RASSF1A, SRC, and CSK (Figure 2E). This
association was in line with a similar role for the homolog
dRASSF8 in Drosophila [30]. To further confirm association, we
employed proximity ligation assays and found that, whereas
both isoforms bind SRC, RASSF1C associated with active
pY416-SRC whereas RASSF1A bound inactive, CSK-phosphor-
ylated, pY527-SRC (Figures 2F and S2A). We next investigated
the effect of RASSF1 isoform modulation of SFK activity. Deple-
tion of RASSF1A alone had no effect on SRC activity, whereas
siRASSF1 led to reduced pY416-SRC in serum or HGF-stimu-
lated cells (Figures S2B and S2C). Conversely, exogenous
expression of RASSF1C elevated pY416-SRC in RASSF1a-me-
thylated colorectal, breast, and lung cancer cells but failed to do
so in unmethylated cells where RASSF1A is expressed (Figures
S2D and S2E) [4]. We therefore hypothesized that RASSF1Cmay
activate SRC but is restricted by competition for association with
higher-affinity RASSF1A and associated CSK. To test this, we
expressed RASSF1C in H1299 cell lines in which RASSF1A
expression was inducible [4] and observed increased pY416-
SRC only in the absence of RASSF1A (Figure S2F). Taken
together, the data indicate that RASSF1A and RASSF1C modu-
late SRC activity by promoting differential phosphorylation
of SRC.(E) Purified protein interaction and immunoprecipitation of GST-tagged CSK, SR
(F) Representative immunofluorescence images showing the different levels of c
SRC (preys) using proximity ligation assay (Duolink) in H1299 cells (left). Graph s
represent 20 mm.
Current BRASSF1C Targets SRC to the Plasma Membrane,
Destabilizing Junctions
Once activated, SRC translocates to the cell membrane and
phosphorylates key target proteins [31]. To determine whether
the activation of SRC by RASSF1C affects the localization, we
tracked GFP-SRC and pY416-SRC by florescence microscopy.
We found that increased pY416-SRC levels in cells correlated
with localization of RASSF1C, endogenous SRC, and pY416-
SRC at the membrane (Figures S3A and S3B), with a significant
increase at cell junctions compared to non-junctional plasma
membrane (Figures 3A and 3B; red versus white arrows). Phos-
photyrosine immunoprecipitates suggest that RASSF1C pro-
motesphosphorylationof junctionproteinsE-cadherin andb-cat-
enin, but not p120-catenin or FAK (focal adhesion kinase)
(Figure 3C). SRC phosphorylation of E-cadherin is known to in-
crease its internalization, subsequently destabilizing cell-cell
junctions [19]. To determine whether RASSF1C-promoted phos-
phorylation of E-cadherin has any effect on E-cadherin junc-
tional integrity, we first took GFP-E-cadherin-expressing cells
where E-cadherin can be visualized at the cell periphery (Fig-
ure 3D). Co-expression of RASSF1C decreased intensity of
GFP-E-cadherin at cell-cell junctions compared to controls but
did not affect a GFP-E-cadherin derivative harboring mutations
in all three SRC phosphorylation sites Y753F, Y754F, and
Y755F [32] (Figure 3D). Moreover, the destabilization of eGFP-
E-cadherin by RASSF1C occurs in a SRC-dependent manner
(Figure S3C). It has been previously shown that loss of junctional
components like a-catenin [33, 34] or E-cadherin [35] leads to
YAP1 nuclear localization. Therefore, we tested whether the
loss of adherens junctions in cells expressing RASSF1C similarly
leads to YAP1 nuclear localization and indeed found RASSF1C
promotes nuclear YAP1, but not in cells expressing E-cadherin
with the SRC phosphorylation sites mutated (Figure 3E). The
fidelity of E-cadherin-mediated junctions relies on continuous
recycling via internalization and replacement through the late
endosomal compartment [36]. Visualization of E-cadherin endo-
some trafficking in real-time via 4D tracking software (Imaris Bit-
plane; ANDOR) indicated that RASSF1C-expressing cells had
reduced trafficking speed and did not register movement toward
the junction, supporting the idea of increased internalization and
failure to recycle (Figures 4A and 4B; Movie S1), a phenomenon
which again was not observed in the case of the E-cadherin
mutant (Figure S4A; Movies S2 and S3). To further determine
the E-cadherin stability at cell-cell junctions, we expressed
GFP-E-cadherin and monitored its dynamics by FRAP analysis,
as has been shown previously [37]. We found that expression of
RASSF1C increased the mobile fraction of E-cadherin and its
turnover at junctions (increased half-life [t 1/2]), but not upon inhi-
bition of SRCwith dasatinib (Figures 4C and S4B; Movies S4 and
S5), suggesting that RASSF1C increased E-cadherin recycling
via SRC, thus creating junctions that are less molecularly stable.
To determine the physical effect on cell-cell adhesion, we em-
ployed a dispase assay and observed that RASSF1C expressionC, and RASSF1A.
olocalization of RASSF1A and RASSF1C (baits) with pY416-SRC and pY527-
howing the quantification of the events per cell is shown (right). All scale bars
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weakened cellular cohesion in a SRC-dependent manner (Fig-
ure 4D). As E-cadherin-mediated adherence relies on Ca2+ for
stable contacts, we next wanted to test whether cell-cell disrup-
tion was indeed due to E-cadherin by employing a Ca2+-switch
assay. We found that, after E-cadherin contacts were efficiently
ablated by removal of Ca2+ from the media, RASSF1C-express-
ing cells failed to efficiently form mature contacts upon Ca2+
replenishment (Figures 4E, S5A, and S5B). The siRNA knock-
down of both SRC and YES endowed resistance to RASSF1C
expression, implicating both in RASSF1C-mediated loss of junc-
tional strength (Figure 4F, right) and E-cadherin intensity (Fig-
ure 4F, left). Taken together, the results indicate that expression
of RASSF1C destabilizes cell-cell junctions and disrupts further
recycling of E-cadherin via SRC. The loss of adherens junctions
can have a wide effect on the cell. Therefore, we next wanted to
further investigate the effect on cells after the loss of E-cadherin.
RASSF1C Promotes YAP and b-Catenin-Dependent
Transcription
Strong E-cadherin contacts require b-catenin, which is protected
from degradation through its interaction with E-cadherin [38].
RASSF1C expression promotes the phosphorylation of b-catenin
(Figure 3C). Moreover, SRC phosphorylation of b-catenin de-
creases its affinity for E-cadherin, leading to dissociation from
themembrane [22, 23]. This allowsnuclear entryand transcription
of target genes. Nuclear-cytoplasmic fractionation and immuno-
fluorescenceanalysis confirmed that eitherRASSF1Cexpression
(in RASSF1A-methylated H1299 and MCF7 cells) or specific loss
of endogenous RASSF1A (U2OS and HeLa cells) increases nu-
clear b-catenin (Figures 5A–5C, S6A, and S6B). We also found
that RASSF1C binds and activates YES1 (Figures 2B and 5D),
known to promoteYAP1 tyrosine phosphorylation that is required
for nuclear localization and accumulation of a b-catenin-
YAP complex [16, 39]. RASSF1C-induced nuclear YAP1 is also
phosphorylated on Y357 (Figures 5D and 5E). Moreover, in
MDA-MB-231mesenchymal breast cancer cells that lack E-cad-
herin junctions, expression of RASSF1C is sufficient to drive
nuclear localization of b-catenin and YAP1 (Figure S6C). b-cate-
nin/YAP1 utilizes the T-box transcription factor TBX5 to drive a
pro-tumorigenic transcriptional program including BCL2L1 and
BIRC5 [16]. TBX5 is primarily linked to congenital heart disease;
however, the homologs TBX2 and TBX3, which share DNA bind-
ing consensus with TBX5, are associated with cancer and inva-
sive cellular behavior [40]. In line with the formation of a YAP1/
b-catenin/TBX complex, we found that loss of RASSF1A, orFigure 3. RASSF1C/SRC Destabilizes E-Cadherin at Cell-Cell Junction
(A) Representative immunofluorescence images showing the localization of SRC
expressing H1299 cells. Graphs represent vector line measurements of eGFP-SRC
including bulk membrane (white arrow) or through two attached cells (A and B) i
(B) Graphs representing the localization of SRC and pY416-SRC at the sites of
mean intensity of the immunofluorescent signal for the indicated antibody and r
experiment.
(C) Phosphotyrosine immunoprecipitation fromMCF7 cells expressing empty vect
displayed images (ImageJ) and are representative of n = 3 experiments.
(D) Fluorescence intensity of MCF7 cells expressing GFP-E-cadherin or GFP-E-
Red-RASSF1C, quantified in graph (right). Quantification of GFP intensity was do
(E) Immunofluorescence detection of YAP1 in MCF7 cells transfected with GFP-E
Representative distribution of DAPI (blue) and YAP1 (black) across equatorial ce
All scale bars represent 20 mm.
Current Bexpression of RASSF1C, similarly induced BCL2L1 and BIRC5
(BCL-xl and survivin; Figures 6A, 6B, S6A, and S6D).
Interestingly, RASSF1C also induces cMYC (Figures 6A, 6B,
and S6A), which is a recognized transcriptional target of b-cate-
nin [41] and YAP/TEAD1 [42] and is bound by TBX3 [28]. Thus,
nuclear YAP1/b-catenin may be directed to a set of survival
and invasive genes via TEAD1/TBX3 transcription factors. The
induction of BCL2L1, BIRC5, and MYC expression by RASSF1C
was reduced by siRNAs targeting either b-catenin/TBX3 or
YAP1/TEAD1, suggesting that the YAP1/b-catenin complex is
recruited via both TBX3 and TEAD1 DNA binding (Figures 6B
and S6D). A reduction in BCL2L1, BIRC5, and MYC expression
was also observed in RASSF1C cells treated with SRC inhibitors,
further implicating that this process is SFK dependent (Fig-
ure S6E) [43]. MYC, as with SRC, is associated with invasive
growth [44]. In agreement with activation of both oncogenes,
RASSF1C promoted motility and invasion and was antagonized
by RASSF1A, independently of other SRC activators identified in
our screen (Figures 6C, 6D, and S6F–S6J). This was not a defect
of attachment or spreading as increased invasion followed in-
duction of RASSF1C expression in attached H1299 cells (Fig-
ure 6E, left) and is dependent on b-catenin, YAP, SRC, and
YES (Figure 6E, right). Together, the data suggest that loss of
RASSF1A promotes invasion via coordinated elevation of
pY357-YAP1 and reduced pS127-YAP1, leading to transcrip-
tional activation of specific TEAD/TBX3 genes.
Expression of RASSF1C Promotes Invasiveness and
Tumorigenesis
To investigate the clinical relevance, we interrogated the data-
bases described above (Figure 1A) for correlations between
pS127-YAP1low and invasive signatures using total YAP1 levels
and the mSigDB database YAP-TAZ signature as a control. We
assessed the extent of increased gene expression from invasive,
metastatic, or EMT signatures but failed to see any highly signif-
icant correlation (p < 0.0001).
We next examined a second breast data set where methyl-
ation of RASSF1A was confirmed in all cases, suggesting that
RASSF1C could be expressed and that loss of pS127-YAP1
can now combine with RASSF1C-promoted pY357-YAP1 to
allow YAP1/b-catenin nuclear localization. In this data set,
pS127-YAP1low (independent of total-YAP1) did indeed have
significantly more genes from invasive, metastatic, and EMT
signatures (POOLA p = 1.09e78; BIDUS p = 4.52e11;
ANASTASIOU p = 2.62e08; Fisher’s exact test). The fact thats
and pY416-SRC at the sites of cell-cell junctions in control and RASSF1C-
(green) and pY416-SRC immunofluorescence (yellow) through a single cell (A)
ncluding junctional membrane (red arrow).
cell-cell junctions in control and RASSF1C-expressing cells in (A). Values are
epresentative of three independent experiments, 15 cells measurements per
or, FLAG-RASSF1A, FLAG-RASSF1C, or both. Bars indicate quantitation of the
cadherin mutant (Y753F, Y754F, and Y755F) with either Ds-Red vector or Ds-
ne on average of ten cells, three independent experiments.
-cadherin or GFP-E-cadherin mutant and either Ds-Red or DsRed-RASSF1C.
ll vector determined by immunofluorescence is shown (right).
iology 25, 3019–3034, December 7, 2015 ª2015 The Authors 3025
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the entire data set is from invasive breast cancers negates direct
mSigDB analysis in different groups; however, we could control
for the increased invasive transcripts in the pS127-YAP1low
group as neither the YAP-TAZ or an unrelated signature dis-
played variation (Figures 7A and S7A; Table S1). We interpret
these data in the breast (II) cohort to imply that the pS127-YA-
P1low group has a YAP/TAZ signature but only an invasive signa-
ture when RASSF1A methylation is 100% penetrant (Table S2).
Interestingly, this group showed significantly lower levels of the
CSK substrate site pY527-SRC and elevated levels of both
BIRC5 and MYC (Figure 7B). Therefore, as RASSF1C is associ-
ated with SRC activation and transcription of these genes, we
decided to investigate whether RASSF1C expression could pro-
mote tumorigenesis in vitro and in vivo. MDA-MB-231 cells, sta-
bly expressing either a control plasmid or RASSF1C, readily
formed mammospheres in Matrigel. However, RASSF1C-asso-
ciated mammospheres were significantly larger and displayed
a more-aggressive phenotype that was SRC, YES, b-catenin,
and YAP dependent (Figures 7C, 7D, and S7B–S7D). In line
with these observations, RASSF1A methylation has recently
been associated with brain metastasis [45]. To directly address
tumorigenesis and invasive spread, we adopted a brain-seeding
model where spread of human cells could be readily traced.
MDA-MB-231 cells stably expressing RASSF1C, injected into
the left striatum of SCID mice, formed significantly larger,
more-aggressive tumors than either naive or empty vector con-
trols (Figure 7E). The results collectively indicate the role of
RASSF1C in invasiveness both in vitro and in vivo. The corrobo-
ration of RASSF1C activity with loss of the RASSSF1A transcript
also supports increasing importance of RASSF1A promoter
methylation with invasion, metastasis, and adverse outcome in
multiple human tumors.
DISCUSSION
SRC and its associated family members play multiple roles in
normal cell homeostasis controlling: cell proliferation and sur-
vival; cytoskeleton organization; cell shape; cell-cell and cell-
ECM contacts; and motility. Deregulation of these activities
promotes tumorigenesis, cancer cell invasion, and metastasis
[46]. Evidence exists for elevation of SRC activity in tumors
as a result of growth factor or cytokine signaling, but a clear so-
matic event is lacking [47]. In addition to mutational events and
copy-number variations that drive tumors, epigenetic alter-Figure 4. RASSF1C Expression Leads to Disruption of E-Cadherin Tra
(A and B) Representative images of the tracking of all the vesicles in control and
(Imaris). Bar graphs (bottom right) show the analysis of the mean speed heatm
analysis, five cells per experiment were used and an average of 700 vesicles wer
Movie S1. Inserts (top) display representative still immunofluorescence images sh
(C) FRAP analysis of RASSF1C-expressing MCF7 cells. (Left) Mobile fraction of t
the return of GFP-E-cadherin at the sites of cell-cell junctions after bleaching in M
displaying junctional GFP-E-cadherin inMCF7 cells, expressing DS-Red or Ds-Re
For each of the three independent experiments, FRAP analysis was done on ten
(D) Quantification of a dispase assay in MCF7 cells expressing Ds-Red or Ds-Red
AZD0530 (2.5 mM; 18 hr) showing number of single cells in suspension.
(E) Quantification of total cell-cell contacts formed in calcium switch assay in M
Representative images for ZO-1 at the sites of cell-cell junctions are shown.
(F) Quantification of a dispase assay (right) and the junctional intensity levels (lef
indicating the level of siRNA knockdown is shown.
Current Bations are known to be a major contributing factor to disease
progression and prognosis. We have identified that, similar to
dRASSF8 binding to dCSK in Drosophila [30], RASSF1A asso-
ciates with CSK and serves to keep SRC repressed. Inactiva-
tion of RASSF1A expression is the most widely observed
epigenetic event across all sporadic human malignancies and
has been confirmed to be a deleterious prognostic factor in
meta-analyses of breast, bladder, lung, colorectal, prostate,
esophageal, and ovarian cancers [10]. Therefore, the absence
of CSK scaffolding to SRC, identified here, is likely to be a
contributing factor in association of RASSF1A methylation
with disease progression. In colorectal cancer, methylation of
RASSF1A is not only associated with tumor dissemination
[10], but it is found to be dramatically elevated in liver metas-
tasis compared to primary tissue [48]. The fact that RASSF1A
cooperates with APC loss to promote intestinal tumors [49]
suggests that SRC activation may contribute to colorectal
tumorigenesis by promoting the tyrosine phosphorylations
of both b-catenin and YAP1 that are required for nuclear
localization and transcriptional activation [16, 29, 39]. These
data therefore provide an explanation for the prognostic value
of RASSF1A methylation, while also providing a biomarker
rational for treating RASSF1A-negative tumors with SRC
inhibitors.
EMT is characterized by loss of cell-cell contacts through inac-
tivation of E-cadherin and gain of mesenchymal markers. We
find that RASSF1C expression in epithelial cells replicates a
partial-EMT phenotype [18] where E-cadherin is expressed,
together with the mesenchymal marker vimentin (data not
shown), but prevented from forming stable contacts. Further,
we observed that RASSF1C expression allows b-catenin and
YAP1, normally sequestered at the membrane, to translocate
to the nucleus. In addition to SRC-mediated destruction of
cell-cell contacts in epithelial cells, we find that mesenchymal
MDA-MB-231 cells also appear to require YES-mediated phos-
phorylation of YAP for nuclear targeting, as has been implicated
previously for RUNX2 complexes [39] and in cancer-associated
fibroblasts (CAFs) in response to mechanical stress [50]. Inter-
estingly, the association of RASSF1A with filamin A and Arp3
(Figure 2A) suggests that actin dynamics and the mechanical
stress response may by sensed by RASSF1A and contribute to
SRC and YAP1 activation. RASSF1C also promotes nuclear
accumulation of YAP1/b-catenin and upregulation of target
genes that promote tumorigenesis, including BCL2L1 andfficking
DsRed-RASSF1C-expressing MCF7 cells, transfected with eGFP-E-cadherin
ap (A) or distance (B) of the vesicles in control and RASSF1C cells. For each
e tracked (bars). The results are from three independent experiments including
owing the accumulation of E-cadherin and the expression of DsRed-RASSF1C.
he return of GFP-E-cadherin after photobleaching is shown. (Right) Halftime of
CF7 cells is shown. (Bottom) Representative still images of Movies S2 and S3
d-RASSF1C, captured prebleach and following bleach. Arrows, bleached area.
cells.
-RASSF1C in the presence or absence of dasatinib treatment (50 nM; 18 hr) or
CF7 cells expressing Zs-green empty vector or Zs-green-RASSF1C. (Bottom)
t) of MCF7 cells transfected with siNT, siSRC, or siYES. (Bottom) Immunoblot
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BIRC5. YAP1/b-catenin promote cancer cell proliferation and
tumorigenesis via TBX5 [16] but also promote overgrowth of
the heart through binding to TEAD [24]. Our data suggest that,
in breast cancer cells, YAP1/b-catenin complex with TBX3,
which phenocopies TBX5 at BCL2L1 and BIRC5 but additionally
promotes cMYC expression, potentially by combining known
TEAD- and TBX3-binding elements [28, 42].
We also confirm that RASSF1A activation of the hippopathway
maintains phosphorylation of YAP1, specifically pS127-YAP1
(Figures 1B and S1A), preventing association with TEAD [6, 15].
Upon loss of the pS127, YAP1 is permissive for activation but
requires additional modifications for nuclear localization and
transcriptional transactivation [15, 16, 29, 39], which we find
are dependent on loss of the RASSF1A transcript and ex-
pression of RASSF1C (Figure 7F). Moreover, YAP-dependent
tumorigenesis, mammosphere formation, and growth in soft
agar have been attributed to BIRC5 expression [16, 42],
which together with MYC-mediated invasion [44] is in line with
the formation of larger, more-aggressive mammospheres in
cells expressing RASSF1C and larger tumors in vivo. These re-
sults also explain the emerging association of both YAP1 and
TBX3 with invasive cancers and motility during development
[51, 52].
These phenotypes are supported by investigation of the clin-
ical data sets that now include CGI methylation and protein
phosphorylation, corroborating links of RASSF1A methylation
with invasive spread and explaining prognostic association of
this epigenetic event. Given the differential regulation of SFK
complexes and YAP activity by RASSF1A and RASSF1C iso-
forms, the balance of expression of these two RASSF1 isoforms
may provide an elegant mechanism for fine-tuning SFK signaling
and YAP1 transcriptional activity during development and in
emerging epithelial cancers. This isoform switch of RASSF1A
may govern further SFK-regulatory events by the RASSF family,
such as RASSF1C homolog Rapl-mediated regulation of SRC
activation in innate immunity [53]. Moreover, is likely to be a com-
mon mechanism that adds complexity to the functionality of ge-
netic information encoded by a single gene.
EXPERIMENTAL PROCEDURES
Proximity Ligation Assay
Proximity ligation assay was performed as described using the Duolink Starter
Kit (Sigma). H1299 cells were transfected and treated as per instructions
before overnight incubation with primary antibodies (SRC, SRC pY416, and
SRC pY527 [Cell Signaling]; ZsGreen [Clontech]; RASSF1A [Epitomics];
RASSF1C [Abcam]; FLAG tag [Sigma]; and HA tag [Millipore]) and secondaryFigure 5. RASSF1C Leads to b-Catenin Nuclear Localization and pY35
(A) Nuclear/cytoplasmic fractionation of U2OS cells transfected with siNT or siR
siRASSF1A are shown (right).
(B) Nuclear/cytoplasmic fractionation (left) and immunofluorescence detection o
(C) Nuclear/cytoplasmic fractionation of H1299 cells transiently transfected with e
FLAG-RASSF1C to show b-catenin localization. (Right) Representative images s
RASSF1C.
(D) H1299 cells transfected with Zs-Green-SRC or Zs-Green-YES and either empt
pY357-YAP1, as indicated.
(E) Immunofluorescence detection of YAP1 and pY357-YAP1 in U2OS cells trans
nuclear/cytoplasmic distribution of YAP1 (right).
All scale bars represent 20 mm.
Current Bantibodies for 1 hr. Hybridization was performed for 30 min in a humidified
chamber, ligation reactions for 30 min, amplification for 100 min, and DAPI
was used for cell detection. The dot-like structures were imaged using Zeiss
LSM780 microscope using a 633 objective. For each cell, five z stack images
were taken and analyzed with BlobFinder V3.2 (Uppsala University) [54]. The
average values, SEM, and significance were calculated using Prism 6.0
(Graphpad) software.
Real-Time Molecular Visualization
MCF7 cells (2 3 105 cells/condition) on glass bottom plates (Ibidi) were trans-
fected with GFP-E-cadherin and DsRed or DsRed-RASSF1C plasmids. Cells
were grown in complete media until imaging, when media was changed to
DMEM/F-12 media without phenol red and supplemented with 10% (v/v)
FBS and 100 U/ml Pen/strep. Cells were imaged using Zeiss LSM780 confocal
microscope using a 633 objective, for the time-lapse one image per second
for a total of 200 s. Tracking of internalized E-cadherin was achieved using
Imaris 7.71 software (Bitplane; ANDOR). Threshold was determined for each
video and varied between 0.4 and 0.6 mm in size. The average distance trav-
eled was set at a threshold of 1 mm. A Quality filter was applied and the
threshold set at 15. The data were extracted using the Vantage feature and
average values, SEM, and significance were calculated using Prism 6.0
(Graphpad) software. On average, five cells and 700 vesicles each were
counted per experiment, and the data shown represent three independent
experiments.
Fluorescence Recovery after Photobleaching
MCF7 cells (2 3 105 cells/condition) were plated on 35-mm glass bottom
plates (Ibidi). Cells were grown in complete media until imaging, when media
was changed to DMEM/F-12 media without phenol red and supplemented
with 10% (v/v) FBS and 100 U/ml pen/strep. Cells were imaged using Zeiss
LSM780 confocal microscope using a 633 (NA 1.4) objective. Each bleach
was done at full laser power, and two pulses were used in order to achieve
60% bleach per region of interest. Images were taken every 2 s for 5 min after
the bleach. Data were analyzed using easyFRAP software [55]. The immobile
and mobile fractions were calculated using double exponential formula (inten-
sity [I] = IE  I1 3 e(t/T1)  I2 3 e(t/T2)).
Animal Experiments
Mice were anesthetized and skull burr-hole drilled. Animals were each focally
injected with 5 3 103 MDA-MB-231 tumor cells expressing empty vector
(pCDNA3) or MYC-RASSF1C in 0.5 ml PBS in the left striatum using a
75-mm-tipped glass microcapillary (Clark Electromedical Instruments). At
day 21, all animals were transcardially perfusion fixed under terminal anes-
thesia (n = 4 per group) and brains were post-fixed, cryoprotected, embedded,
and frozen in isopentane at 40C. To assess areas of tumor colonization,
photomicrographs of each brain section were obtained using ScanScope
CS slide scanner (Aperio) and analyzed using ImageScope (Aperio). For immu-
nofluorescence, sections were streptavidin and biotin blocked, incubated with
anti-CD34 primary antibody (Abcam; brain vessels) or anti-vimentin antibody
(VectorLabs; tumor cells), washed, and incubated with a streptavidin-Cy3
fluorophore or AMCA-conjugated secondary antibody (Invitrogen; 1:100) for
30 min. Expanded animal experimental procedures are outlined in Supple-
mental Experimental Procedures.7
ASSF1A (left). Representative images of U2OS cells transfected with siNT or
f b-catenin (right) of HeLa cells transfected with siNT or siRASSF1A.
mpty vector, FLAG-RASSF1A, FLAG-RASSF1C, or both FLAG-RASSF1A and
how b-catenin localization in H1299 transfected with empty vector or FLAG-
y vector or FLAG-RASSF1C and blotted for pY416-SRC, YAP, and the SFK site,
fected with siNT, siRASSF1, or siRASSF1A (left) and immunoblot showing the
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Figure 6. RASSF1C Promotes YAP1-Dependent Transcription and Cell Motility
(A) Quantification of qRT-PCR for the b-catenin-YAP target genes BCL2L1, BIRC5, and cMYC as well as RASSF1A and RASSF1C expression in U2OS cells
transfected with siNT, siRASSF1, or siRASSF1A.
(B) Quantification of qRT-PCR for the b-catenin-YAP target genes BCL2L1, BIRC5, and cMYC in MCF7 cells transfected with empty vector or FLAG-RASSF1C
and indicated siRNAs.
(C) Scratch wound motility assay of HeLa cells transfected with non-targeting siNT, siRASSF1, and siRASSF1A (left). Wound healing motility assay of MDA-MB-
231 cells transfected with empty vector, FLAG-RASSF1A, FLAG-RASSF1C, or both FLAG-RASSF1A and FLAG-RASSF1C is shown (right).
(D) Quantification of a Transwell assay with MDA-MB-231 cells expressing empty vector, FLAG-RASSF1A, FLAG-RASSF1C, or both.
(E) Migration assay in real time using ExCELLigence analyzer with H1299.R1CDox TET-ON FLAG-RASSF1C inducible cells (right) or controls H1299.ConDox TET-
ON empty-vector-inducible cells (left) in the presence or absence of 1 mg/ml doxycycline. (Right) Migration assay in real time using ExCELLigence analyzer on
MCF7 cells transfected with empty vector or FLAG-RASSF1C with siNT, siYAP1, sib-catenin, siSRC, or siYES is shown.
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All animal experiments were approved by the University of Oxford local an-
imal ethical committee and were performed according to terms of a license
granted by the UK Home Office, adhering to the Animals (Scientific Proce-
dures) Act 1986.
The Cancer Genome Project Analysis
The data were downloaded from cBioPortal for Cancer Genomics [56, 57] and
analyzed with SPSS 21.0 and R version 3.0.1 software. For each clinical data
set, cases with missing (NA) methylation, protein, or gene expression values
were excluded where appropriate. The Shapiro-Wilk test was used to assess
distribution of data sets, null hypothesis of normal distribution was rejected
at p < 0.05 level, and the non-parametric Spearman-Rho test was used
for correlation. The non-parametric Kruskal-Wallis or Jonckheere-Terpstra
was used to compare the differences of either protein or gene expression
levels between the appropriate groups analyzed. The Molecular Signatures
Database (MSigDB v4.0) [58] was used to select gene sets, and POOLA_
INVASIVE_ BREAST_ CANCER_ UP [59], BIDUS_ METASTASIS_ UP [60],
ANASTASSIOU_ CANCER_ MESENCHYMAL_ TRANSITION_ SIGNATURE
[61], CORDENONSI_ YAP_ CONSERVED_ SIGNATURE [62], REACTOME_
YAP1_ AND_ WWTR1_ TAZ_ STIMULATED_ GENE_ EXPRESSION, and
BLALOCK_ ALZHEIMERS_ DISEASE_ INCIPIENT_ UP [63] were selected as
either test or control gene signature sets. The non-parametric Mann-Whitney
test was used to compare variation in gene expression between the groups
analyzed and the Fisher’s exact test used to compare differences in frequency
distributions.
Statistics
For all in vitro experiments, statistical analysis was carried out using a Stu-
dent’s t test. Tumor areas were compared by ANOVA followed by post hoc
Newman-Keuls t tests. All data are expressed as mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, two tables, Supplemental
Experimental Procedures, and five movies and can be found with this article
online at http://dx.doi.org/10.1016/j.cub.2015.09.072.
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